Matthew Tran

Matthew Tran supports the Food and Drug Administration’s Office of Acquisition and Grant Services in executing mission-critical procurement activities that sustain regulatory science and laboratory infrastructure. He manages acquisitions for professional services essential to the FDA’s public health mandate, including scientific consulting, analytical testing, and research support. His work directly enables the agency’s ability to evaluate drug safety, validate medical device performance, and advance regulatory science through high-precision technical services. Tran typically handles task orders and indefinite-delivery/indefinite-quantity contracts under broad agency-wide procurement vehicles, ensuring timely access to specialized expertise across the biomedical research lifecycle. He maintains consistent contracting relationships with key vendors including Tranquil Clinical and Research Consulting Services LLC, Toxicologic Pathology Associates Inc., and Progenics Pharmaceuticals Inc., reflecting a preference for niche, domain-specific providers with deep expertise in preclinical research, toxicology, and clinical trial support. These partnerships are characterized by repeat engagements and long-term service alignment, indicating a focus on continuity, technical reliability, and institutional knowledge rather than broad-based competition. His contracting patterns prioritize subject-matter expertise over volume, fostering trusted vendor relationships critical to the FDA’s scientific integrity. Tran’s procurement portfolio reflects a 100% non-set-aside orientation, with no reliance on 8(a), HUBZone, SDVOSB, or other socioeconomic programs. This indicates a strategic emphasis on technical capability and domain specialization over socioeconomic criteria, aligning with the FDA’s need for highly qualified providers in regulated scientific environments where certification status is secondary to proven competency in regulatory science. His primary NAICS focus is 611430 (Professional and Management Development Training), reflecting substantial investment in workforce development for regulatory staff, complemented by 20% each in 541380 (Testing Laboratories and Services) and 813910 (Business Associations). This underscores his expertise in procuring analytical testing services, scientific training programs, and industry association collaborations that enhance the FDA’s technical capacity and stakeholder engagement in regulatory science.